PCN103 Reanalysis of Cost-Effectiveness of Abiraterone Acetate as Second Line Treatment for Metastatic Castration-Resistant Prostate Cancer in Japan Using a Japanese Claim Data Set  by Shibahara, H. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A85
PCN101
The effeCT of herd ImmuNITy IN dIffereNT humaN PaPIllomavIrus 
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Objectives: Italian recommendations for human papillomavirus (HPV) immu-
nization currently consider females only. However, males can be vectors in viral 
transmission and at risk of infection. The BEST II study was designed to evaluate: 
the cost-effectiveness (CE) of different interventions targeting females as well as 
males; and the economic impact of vaccination on a wide range of HPV-induced dis-
eases. MethOds: A dynamic Bayesian Markov model was developed to investigate 
the transmission between sexual partners and the cost-effectiveness of vaccination 
targeting female and male cohorts in comparison to screening and female cohorts 
only. A range of HPV-induced diseases was considered (cervical, vaginal, vulvar, 
anal, head and neck and penile cancer, the associated pre-cancerous stages and 
anogenital warts). The process of sexual mixing was calculated based on age, gender 
and sexual behavioural specific matrices to estimate th force of infection dynami-
cally. Increased susceptibility to the virus, associated with early sexual début, a high 
number of partners, smoking and previous STDs, were included. We considered 
several scenarios; the baseline assumes universal vaccination to be implemented 
for 12-year-old females and males. The follow-up period was 55 years. Results: 
According to our preliminary analysis, universal vaccination resulted in incremental 
CE ratios (ICERs) corresponding to € 910 and € 5,770, when compared to screening-
only and female-only vaccination, respectively. We performed extensive sensi-
tivity analysis, which confirmed the good CE profile of universal vaccination in 
Italy. cOnclusiOns: A universal HPV vaccination of male and female programme 
is more cost-effective than screening and female-only vaccination when account-
ing for all HPV-related diseases. Universal vaccination programme increase herd 
immunity and provide indirect protection to unvaccinated girls against HPV. The 
herd immunity plays a significant role in the economic evaluation of HPV immuni-
zation programmes. A universal vaccination may be further useful considering that 
males are both at risk of infection and vectors in viral transmission.
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ComPared wITh fludaraBINe-rITuxImaB TreaTmeNT, IN PaTIeNTs wITh 
INdoleNT NoN-hodgkIN’s lymPhoma IN CosTa rICa
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Objectives: To assess the cost-effectiveness of Bendamustine-Rituximab (BR) 
compared with Fludarabine-Rituximab (FR) treatment, in patients with Indolent 
Non-Hodgkin’s Lymphoma (INHL) that have progressed during or within six 
months of treatment with Rituximab or a Rituximab-containing Regimen in Costa 
Rica. MethOds: A three-health state cohort simulation Markov Model (progres-
sion-free, progressive disease, and death) was developed based on time-dependent 
progression-free survival and overall survival data. The time frame was lifetime (35 
years). The perspective was that of the National Health System of Costa Rica. The 
health outcomes of interest were Quality Adjusted Life Years (QALYs), Life Years 
(LYs), and Progression-free Life Years (PFLYs). Resource consumption for health 
states was elicited with the support of Latin American hematologists. Utilities for 
health states and disutility for adverse reactions were taken from published studies. 
All costs and Incremental Cost Effectiveness Ratios (ICERs) are presented in Costa 
Rican currency (Colones). Costs and outcomes were discounted at 3%. One way 
and probabilistic sensitivity (PSA) analysis were performed. Results: BR resulted 
in 4,641 QALYs/ 6,432 LYs/ and 3,564 PFLYs, per patient, respectively. FR resulted in 
3,557 QALYs/5,138 LYs and 2,047 PFLYs, per patient, respectively. Total costs were: 
76.309.813 for BR and 73.045.490 for FR. ICERs were: 3.013.664 per QALY gained, 
2.523.307 per LY gained and 2.151.945 per PFLY gained. In all outcomes, results 
were highly sensitive to Hazard Ratio of overall survival. According to the PSA, 
with QALYs as outcome, BR had a probability of 63% of being cost effective when 
considering the threshold of 3 times the Gross Domestic Product per capita (GDPPC) 
of Costa Rica (14.140.792). cOnclusiOns: BR can be considered very cost-effective 
compared with FR in the study population (INHL) in Costa Rica, according to the 
threshold suggested by the World Health Organization [very cost effective below 
1 GDPPC (4.713.597)].
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Objectives: The objective of this study is to evaluate cost-effectiveness of abirater-
one plus prednisolone compared to prednisolone alone in Japan. We presented the 
result of the cost-effectiveness analysis of abiraterone acetate in 2013 ISPOR Europe 
Congress. In the present study we reanalyze the cost-effectiveness of abiraterone 
by referencing the real world resources using a Japanese claim data set. MethOds: 
Cost-effectiveness analysis was performed using a Markov model based on data 
from the randomized controlled trial (COU-AA-301 study) and literature review 
conducted from the public health care payer’s perspective. The abiraterone plus 
prednisolone was compared with prednisolone alone. The base case was assumed 
to be a 72 year-old man with metastatic castration-resistant prostate cancer (CRCP). 
The model used a time horizon of 10 years. Outcomes were measured in quality-
Medicare beneficiaries aged ≥ 66 diagnosed with HM between January 1, 1995 and 
December 31, 2007, including: acute myeloid leukemia (AML, n= 10,173); chronic lym-
phocytic leukemia (CLL, n= 13,743); chronic myelogenous leukemia (CML, n= 4,169); 
Hodgkin lymphoma (HL, n= 2,252); non-Hodgkin lymphoma (NHL, n= 51,087); and 
multiple myeloma (MM, n= 18,297). We used a discrete hazard model to estimate 
survival and projected lifetime costs using a generalized linear model with a log-
link and gamma distribution. Models were adjusted for year of diagnosis, age, race, 
gender, and comorbidity. We calculated the incremental cost-effectiveness ratio 
(ICER, measured in terms of cost per life year [LY]) using cost and survival differences 
between the earliest (1995-1998) and latest (2005-2007) time periods. Costs were 
standardized to year 2010 dollars. Results: HM survival among Medicare patients 
increased during the time period studied, though gains varied by diagnosis. Care 
costs for all diagnoses also increased over time, especially for HL (from $148,000 
for individuals diagnosed during 1995-1998 to $230,000 for a 2005-2007 diagnosis) 
and NHL (from $158,000 for patients diagnosed during 1995-1998 to $247,000 for 
a 2005-2007 diagnosis). Survival gains were most cost-effective for CML ($37,877/
LY) and least cost-effective for HL ($94,859/LY). The ICERs were $43,262/LY for CLL, 
$59,355/LY for MM, $62,127/LY for NHL, and $83,392/LY for AML. cOnclusiOns: Our 
findings suggest that over a period of more than a decade, improvements in treat-
ment for HM have been associated with gains in survival, but also with substantial 
increases in health care costs. Overall, HM therapy innovations appear to provide 
good value for money among Medicare patients when evaluated using conventional 
cost-effectiveness metrics.
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Objectives: Sunitinib is one of the first targeted treatments for metastatic renal 
cell carcinoma (MRCC) and is currently considered as the standard of care for 
most of the MRCC patients in the first-line setting. Sunitinib delays disease pro-
gression, with a median overall survival of more than 2 years, improves quality 
of life and is becoming the first-line standard of care for MRCC. The introduction 
of targeted treatments, led to improvements in disease management and sur-
vival of these patients, however, with increasing cost. Purpose this reserch - to 
assess the economic value of sunitinib as first-line therapy in MRCC within the 
Kazakh health care system. MethOds: Cost-effectiveness of sunitinib has been 
assessed on several occasions and a systematic literature search was conducted 
to find all published research articles as well as all research abstracts presented 
in various congresses. An adapted Markov model with a 10-year time horizon 
was used to analyse the cost effectiveness of sunitinib vs. sorafenib (SFN) and 
bevacizumab/interferon-α (BEV/IFN) as first-line MRCC therapy from the Kazakh 
perspective. Results: Progression-free survival and overall survival data from 
sunitinib, SFN and BEV/IFN pivotal trials were extrapolated to project survival 
and costs in 6-week cycles. Results, in progression-free life-years (PFLY), life 
years (LY) and quality-adjusted life-years (QALY) gained, expressed as incremen-
tal cost-effectiveness ratios (ICER) with costs and benefits discounted annually 
approximate 3%, were obtained using deterministic and probabilistic analyses. 
Sunitinib was more effective and less costly than both SFN and BEV/IFN with 
average cost savings/patients, respectively. Using a willingness-to-pay threshold, 
sunitinib achieved an incremental net benefit compared with SFN and BEV/IFN, 
respectively. At this willingness-to-pay, the probability of sunitinib providing the 
highest incremental net benefit was 72%. cOnclusiOns: Our analysis suggests 
that sunitinib is a costeffective alternative to other targeted therapies as first-line 
MRCC therapy in the Kazakh health care setting.
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Objectives: Whether the addition of radiation therapy (RT) improves overall 
cost effectiveness in men with locally advanced prostate cancer managed with 
androgen deprivation therapy (ADT) is still unclear. Our objective was to conduct 
cost-effectiveness analysis of adding radiation therapy to androgen deprivation 
therapies in men with locally advanced prostate cancer in the U.S.A. MethOds: A 
decision analysis model was designed to compare adding RT to ADT over a 10 year 
time horizon with the third party payer’s perspective. Probabilities of treatment 
success, utilization of salvage treatments, and rates of adverse events were taken 
from published results of SPCG-7/SFUO-3 trial and NCIC CTG PR.3/MRC UK PR07 
trial. Cost inputs were based on 2010 Medicare reimbursement rates and reported 
in 2013 US dollars. Primary outcome measure was incremental cost per biochemi-
cal success (i.e. serum PSA level < 0.4 ng/ml). 50,000 U.S. dollars were considered 
willingness to pay threshold. A series of one-way sensitivity analyses and Monte 
Carlo simulation was performed by testing variations in the range of the 95% con-
fidence interval. Results: ART results in a higher biochemical success rate than 
hormonal therapy with a probability of 0.30 versus 0.21. The mean incremental 
effect was 0.6 over a 10-year period. Total cost of ART was $25,783 compared with 
costs in the ADT group of $13,427 per year, the mean incremental cost for ART ver-
sus ADT was $8,277 over 10 year period. The mean incremental cost effectiveness 
ratio was $13758 over 10 year period. Cost-effectiveness acceptability curve analysis 
resulted in > 90% probability that ART with hormonal therapy is cost-effective strat-
egy. cOnclusiOns: Study suggests that adding RT to ADT is cost effective strategy 
compared to ADT alone based upon the decision analysis model for appropriate men 
with locally advanced prostate cancer. The study limitations and treatment dosage 
should be considered before applying the results of the study.
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and medications were taken from official sources and an institution of national 
reference of oncology services. The safety and effectiveness data were taken from 
the literature and two Colombian cohorts (one retrospective and one prospective) 
with patients older than 15 years. The unit of outcome was the proportion of deaths 
averted. The incremental cost effectiveness ratio (ICER) was estimated, univari-
ate sensitivity and probabilistic analysis were performed. Results: Model results 
indicate that under the scenario of a clinical trial not using factor was a dominated 
alternative (ICER of - 61,753,681 COP per death averted). In contrast, using data from 
the Colombian cohorts, factor was dominated strategy (ICER of - 141,421,622 COP 
for retrospective cohort and prospective cohort -215,449,438 COP). The variable that 
most impacted the outcome was the incidence of febrile neutropenia (12% for the 
clinical trial, 60% retrospective cohort and 83% prospective cohort). The results were 
robust to the probabilistic sensitivity analysis. With the data from the clinical trial 
in 94% of cases using factor was cost effective, while in the Colombian data in 84% 
and 72% of cases (retrospective and prospective cohort respectively) was not cost 
effective to use factor. cOnclusiOns:: With Colombian information the prophy-
lactic use of the factor under chemotherapeutic induction in adults with ALL turns 
out to be not cost-effective. The gap in the results suggests a careful extrapolation 
of information from clinical trials (ideal world) to develop economic evaluations in 
Colombia, and its impact on decision making.
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Objectives: Analyze the cost-effectiveness of full-field digital mammography (DM) 
compared to the screen-film mammography (SFM) among different age groups of 
Mexican women. MethOds: A cost-effective study was developed - from the public 
sector perspective- to estimate the cost per cancer detected by DM vs. SFM in the 
following age groups: 40-49, 50-59 and 60-69 years old. Additional costs and effects 
were estimated by comparing DM against SFM and expressed as incremental cost-
effectiveness ratio (ICER). The outcome was the number of detected cases. Staff 
wages and tests cost (mammography, ultrasound and biopsy) were included. An 
univariate sensitivity analysis was carried out with key variables. Results: DM is 
more expensive and more effective than SFM for breast cancer detection. Using DM 
for 50-59 age group is not cost- effective since it detects fewer cases at a higher cost. 
In the 40-49 age group, the ICER for DM was $318,828 per additional case detected, 
while in the 60-69 the ICER for DM was $255,636. The ICER was sensitive to the lower 
cost of DM. cOnclusiOns: For some age groups, DM is more effective than SFM; 
however, DM cost limits its use in a screening program. Evidence shows, SFM still 
has advantages in detecting breast cancer at an affordable cost. Further research 
taking into consideration social, organizational and staff training issues is important
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eCoNomIC model To value ComPaNIoN dIagNosTICs IN advaNCed/
meTasTaTIC CaNCer TreaTmeNT
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Objectives: Many targeted anticancer drugs under development will be used with a 
companion diagnostic. The objective of this study was to define parameter values that 
will be included in a global model estimating the cost-effectiveness of a companion 
diagnostic in advanced/metastatic cancer treatment. MethOds: As the model will 
be generic to allow its use in the most common cancers in Canada (breast, prostate, 
lung, colorectal, bladder, cervical, non-Hodgkin’s lymphoma), specific parameters 
for each cancer of interest (including health state utilities and costs associated with 
cancer management) were considered. Consequently, a literature review was con-
ducted using electronic databases from January 2000 until September 2013 to extract 
these parameters in economic models in advanced/metastatic cancer available. Cross-
references studies and governmental publications were also consulted. Canadian 
costs and disutilities associated with any grade 3-4 treatment-related adverse events 
(AEs) were also obtained. Results: Lung cancer was associated with the highest 
inpatient cost ($CAN19,875/stay of 9.9 days on average), while patients with prostate 
cancer incurred the highest cost associated with emergency visits ($CAN721.55/case). 
Costs associated with end-of-life care were similar among cancer types, with an aver-
age cost of $CAN31,081/case and 152 days of end-of-life care. Thirty-nine AEs were 
retrieved. Costs associated with management of AEs were up to $CAN71,967/case 
(development of secondary malign neoplasm), with an average cost of $CAN7,717/
event. Disutilities associated with the incidence of AEs were up to 0.465 (hip fracture), 
with an average utility loss of 0.135. Lung cancer presented the worst health state 
utility values (0.611 in pre-progression and 0.441 in progression). cOnclusiOns: 
Although the model structure and key elements required to assess the cost-effec-
tiveness of a companion diagnostic can be generalized to different cancer types, this 
study suggests that parameter values should be specific to the cancer of interest.
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Objectives: Screening of all patients diagnosed with colorectal cancer for Lynch 
syndrome using a staged testing procedure is currently recommended by Evaluation 
of Genomic Applications in Practice and Prevention (EGAPP) guidelines. Next gen-
eration sequencing (NGS) is a disruptive technology that likely offers improved 
outcomes, but its value is uncertain. The goal of this study was to evaluate the 
cost effectiveness of NGS vs. tumor tissue testing for universal testing of patients 
with colorectal cancer (CRC) to detect relatives with Lynch syndrome. MethOds: 
adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) was 
calculated. As Japanese Ministry of Health, Labour and Welfare has not yet approved 
abiraterone due to the delay in development, the drug cost was estimated based 
on prices in four other countries. In the present study, resource use was estimated 
using a Japanese claim data set with 2000 claim data of prostate cancer patients 
from January 2005 to March 2013. Both cost and outcomes were discounted at a 
2% annual rate. Results: The result of this study revealed that abiraterone plus 
prednisolone indicated higher QALYs than prednisolone alone. In the base-case 
analysis, ICER for abiraterone plus prednisolone exceeded JPY 17 million (roughly 
EUR 120,000) per QALY gained. One-way sensitivity analysis for the price of abira-
terone influenced ICER (JYP 12.5 - 21 million). cOnclusiOns: The present study 
suggested that the ICER is more than JPY 10 million. Further deliberate discussion 
on cost-effectiveness of abiraterone in Japan is needed to consider the Japanese 
price and clinical outcomes.
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Objectives: NADiA ProsVue is a prognostic system developed to identify men at 
lower risk for clinical recurrence of prostate cancer following radical prostatec-
tomy, as indicated by a prostate-specific antigen (PSA) slope < = 2 pg/mL/month. 
We evaluated the potential cost-effectiveness of using the prognostic system to 
guide adjuvant radiotherapy (ART) in men considered to be at intermediate- or 
high-risk for recurrence based on the CAPRA-S nomogram. MethOds: We devel-
oped a decision analytic model consisting of a decision tree to stratify men into 
risk groups and a state transition model to generate long-term costs and outcomes. 
We derived model parameters using patient-level data from the product’s 510(k) 
registration study, the medical literature and other sources. We conducted probabil-
istic, one-way and two-way sensitivity analyses to examine the cost-effectiveness 
of the system (i.e. with PSA slope findings) versus standard care (i.e. without PSA 
slope findings). Results: The cost-effectiveness of a PSA slope-guided strategy 
varied widely due to small differences in QALYs at 10 years. Assuming that 20% of 
men in the intermediate-risk CAPRA-S group receive ART with standard care, the 
incremental cost-effectiveness ratio (ICER) is less than $50,000 per QALY when use 
of ART is less than 8.2% among men with PSA slopes < = 2 pg/mL/month. Assuming 
that 40% in the high-risk CAPRA-S group receive ART with standard care, ART would 
have to decrease to at least 11.5% among men with PSA slopes < = 2 pg/mL/month to 
achieve an ICER less $50,000 per QALY. ICERS were also sensitive to varying the costs 
of the prognostic system and ART, varying the benefits of salvage therapy and utility 
weights for ART toxicities. cOnclusiOns: The ProsVue system has the potential 
to be cost effective, but its value will be dependent on the magnitude of reduction 
in ART among men identified as having a low risk of recurrence.
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Objectives: To evaluate the clinical and economic tradeoffs associated with 
FOLFIRI + either cetuximab or bevacizumab as 1st-line therapies among KRAS wild 
type (WT) metastatic colorectal cancer (mCRC) patients, through a cost-effective-
ness analysis incorporating Phase III FIRE3 clinical trial data. MethOds: A deter-
ministic cost-effectiveness model was developed to project lifetime survival and 
costs of FOLFIRI used with either cetuximab or bevacizumab. A cohort of 1st-line 
patients faced risks of adverse events, progression to 2nd-line treatment, or eligibility 
for curative liver resection. Clinical trial data, published literature, and publicly avail-
able databases were used to estimate model inputs. Incremental cost-effectiveness 
ratios (ICERs) were calculated as 2013 US$ per life year (LY) and per quality-adjusted 
life year (QALY). We conducted a scenario analysis to analyze the subset of RAS WT 
patients. The impact of parameter uncertainty was also evaluated with one-way and 
probabilistic sensitivity analyses. Results: Compared with 1st-line bevacizumab 
KRAS WT patients, those treated with cetuximab gained an additional 5.7 months of 
life (42.9 vs. 37.2) at a cost of $46,301 ($280,933 vs. $234,632), for an ICER of $97,297/LY 
($122,704/QALY). The benefits of cetuximab were also greater for RAS WT patients, 
for whom the ICER was $77,380/LY ($99,636/QALY). Treatment with cetuximab would 
be cost effective 53.6% of the time, given a willingness to pay threshold of $100,000/
LY. Results were most sensitive to changes in 1st-line survival, treatment duration, 
and product acquisition costs. cOnclusiOns: Treatment with cetuximab + FOLFIRI 
in 1st-line mCRC patients may improve health outcomes and use financial resources 
more efficiently than bevacizumab + FOLFIRI, given current societal standards. This 
information can be useful to clinicians, payers, and policy makers in making treat-
ment and resource allocation decisions for KRAS WT and RAS WT mCRC patients.
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Objectives: To determine the cost-effectiveness of prophylactic administration 
of Filgrastim compared with no use, during the induction phase of chemother-
apy in adults with Acute Lymphoblastic Leukemia (ALL) in the Colombian con-
text. MethOds: A decision tree with a time horizon of 30 days is built under the 
third-party payer perspective including only direct costs. The costs of procedures 
